Eloxx Pharmaceuticals stock fell 1.82 percent on October 6, 2026
Published on 10/07/2026 at 06:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eloxx Pharmaceuticals stock fell 1.82 percent to USD 15.13 on October 6, 2026, at 4:00 p.m. ET. The price was 35.34 percent below the 52-week high of USD 23.40, keeping the company’s clinical pipeline and financing position central to the investment case.
Filing adds financing context
According to Stock Titan, Eloxx filed a Form S-1 on September 11, 2026, covering the resale of 600,000 common shares and up to 4,358,919 shares issuable through pre-funded warrants. The company itself is not selling the registered shares.
The filing states that the warrants carry an exercise price of USD 0.11 per share and that Eloxx would receive USD 0.5 million if all of them were exercised for cash. The structure therefore creates a potential share-supply overhang while offering limited direct funding to the company.
Clinical progress meets operating losses
Eloxx is a clinical-stage biotechnology company developing exaluren, a ribosome-modulating candidate for rare diseases caused by nonsense mutations. The same Stock Titan filing says the company began dosing patients in a Phase 2b study for nonsense-mutation Alport syndrome in the third quarter of 2026.
For the six months ended June 30, 2026, the filing reports a net loss of USD 8.3 million and an accumulated deficit of USD 308.8 million. The figures underline why clinical execution and access to additional capital matter more than product revenue at this stage.
Analysts see a wide valuation gap
Investing.com listed a Strong Buy consensus from 4 analysts on September 18, 2026. The average 12-month target was USD 38.25, with a low of USD 32.00 and a high of USD 43.00.
The average target stood 152.81 percent above the October 6 price of USD 15.13. That gap reflects the market's dependence on trial milestones rather than established commercial sales, while the S-1 filing highlights dilution and reporting-compliance risks.
Stock remains below yearly high
Eloxx stock was last at USD 15.13 on Nasdaq on October 6, 2026, with a session range of USD 14.50 to USD 16.02. Its market capitalization was USD 52.0 million, and trading volume reached 61,282 shares.
Eloxx Pharmaceuticals stock facts
- Company: Eloxx Pharmaceuticals, Inc.
- Ticker: ELOX
- Trading venue: Nasdaq Capital Market
- Price (as of October 6, 2026, 4:00 p.m. ET): USD 15.13
- Market capitalization: USD 52.0 million (as of October 6, 2026)
- 52-week range: USD 8.20-23.40 (as of October 6, 2026)
- Sector / Industry: Biotechnology
